CAR-T treatments have not yet been globally trialled for use in T-cell lymphoma, due to the
difficulty in identifying a protein that is unique to the T-cell malignancy, but not present on
the patients’ own normal T-cells. The Hudson Medical Research Institute have been
conducting preliminary laboratory experiments looking at a protein called CTH01, which
seems to meet this criterion. Preliminary lab data suggest a CAR-T product using this protein
can be manufactured in the lab, and is effective in killing skin lymphoma cells in laboratory
We are supporting research to produce and manufacture this novel CAR-T product at scale, and to then undertake a world-first clinical trial of this cellular product in patients with cutaneous T-cell lymphoma.
Thank you to the Eva & Les Erdi Humanitarian Charitable Foundation, Perpetual IMPCT Philanthropy and anonymous donors for their support.
Three year project of $600,000 is needed (grant application is for 2 of the 3 years)
Total Project cost: $600,000
Funding received to date: $530,000